Home Lilly Discontinues Phase 3 Rheumatoid Arthritis Program For Tabalumab Based On Efficacy Results
 

Keywords :   


Lilly Discontinues Phase 3 Rheumatoid Arthritis Program For Tabalumab Based On Efficacy Results

2013-02-08 09:17:08| Biotech - Topix.net

Eli Lilly and Company announced today that it will discontinue the Phase 3 rheumatoid arthritis program for tabalumab, an anti-BAFF monoclonal antibody, due to lack of efficacy.

Tags: results based program phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
21.09Strategies to minimize fallback pigs in the nursery
21.09This Week in Agribusiness, Sept. 21, 2024
21.09This Week in Agribusiness, Sept. 21, 2024
21.09RABapp provides rapid response insight in animal health emergencies
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
21.09Weekly Recap: PPG, Axalta, AkzoNobel Top This Weeks Stories
21.09Atlantic Tropical Weather Outlook
More »